Changjiang Life Technologies recorded a shareholder profit of HK$1.73 billion in 2023, a significant decrease of 87% compared to HK$13.2 billion in 2022. The decrease was mainly due to an increase in financial costs of HK$1.59 million. If interest rates remain at 2022 levels, the profit attributable to shareholders in 2023 will reach HK$1.805 million, an increase of approximately 37%. Over the past three years, companies have faced environmental challenges such as inflation, labour shortages and supply chain disruptions, but have responded with measures such as raising prices, streamlining operations and improving efficiency. The company does not propose a final dividend in 2023. In healthcare R&D, the company focuses on the development of cancer treatment and early detection programs and advances in therapeutic cancer vaccine research...Show More

Changjiang Life Technologies recorded a shareholder profit of HK$1.73 billion in 2023, a significant decrease of 87% compared to HK$13.2 billion in 2022. The decrease was mainly due to an increase in financial costs of HK$1.59 million. If interest rates remain at 2022 levels, the profit attributable to shareholders in 2023 will reach HK$1.805 million, an increase of approximately 37%. Over the past three years, companies have faced environmental challenges such as inflation, labour shortages and supply chain disruptions, but have responded with measures such as raising prices, streamlining operations and improving efficiency. The company does not propose a final dividend in 2023. In healthcare R&D, the company focuses on the development of cancer treatment and early detection programs and advances in therapeutic cancer vaccine research. The healthcare products business performed well in 2023, with a profit contribution of HK$2.83 million, up 8% from 2022. Agri-related businesses also recorded a profit contribution of HK$3.5 billion, an increase of 4%. The Company's total assets are HK$112.474 billion and total net assets are HK$41.893 billion, equivalent to HK$0.44 per share. Chairman of the Board, Mr. Li, presented his Annual Report in Hong Kong on 19 March 2024.